Background
==========

Type 2 diabetes (T2D) is associated with obesity. There is increasing evidence that T2D is associated with tumors \[[@B1]\] and cancers of the pancreas \[[@B2]\], prostate, breast, colon, endometrium, and liver \[[@B3]\]. T2D genes, such as *HNF-1 beta*and *JAZF1*, have been associated with prostate cancer \[[@B4]-[@B6]\]. Thus, T2D candidate genes may not only be obesity predisposing genes, but also tumor/cancer risk genes. CHOP mediates apoptosis and regulates mitochondrial gene expression, thus it may be implicated in beta cell inability to replicate as well as in insulin secretion defects. Following up on a linkage signal in the *CHOP*region of chromosome 12q13.1 in Italian T2D families, we have previously shown that *CHOP*5\'UTR-c.279T\>C and +nt30C\>T haplotype variants are associated with early-onset T2D under a recessive and additive model \[[@B7]\]. In addition, CHOP inhibits adipogenesis \[[@B8]\], thus *CHOP*gene variants may contribute to insulin resistance \[[@B9],[@B10]\] and/or obesity \[[@B11]\]. Since CHOP is regulating programmed cell death in response to stress stimuli \[[@B12]\], it is implicated in tumor/cancer development.

CHOP is involved in the pathogenesis of myxoid liposarcoma, a rare human tumor in which a reciprocal chromosomal translocation creates a fusion protein consisting of CHOP and TLS, a potent oncoprotein \[[@B13]\]. Other tumor-specific fusion genes, such as *EWS-CHOP*and *TLS/FUS-CHOP*, have been detected in solid tumors \[[@B14]\] and liposarcomas \[[@B15]-[@B17]\]. Another rearrangement of the *CHOP*gene has been reported in myxoid liposarcoma \[[@B18]\].

Our aim was to find whether there is any association of the *CHOP*5\'UTR-c.279T\>C and +nt30C\>T genotypes and corresponding haplotypes (the latter contributing to T2D) \[[@B7]\] with body mass index (BMI) ≥ 25 (hereby defined as overweight condition/pre-obesity) and/or with tumors/cancer in an Italian dataset.

Methods
=======

We recruited from the general population in Italy 45 subjects with BMI ≥ 25 and 44 control subjects with BMI \< 25 and 54 subjects with at least one cancer or at least one tumor and 43 control subjects with no history of tumor or cancer. We obtained the written informed consent from each subject and the approval from the Institutional Review Board accordingly to Helsinki Declaration guidelines. DNA samples were directly sequenced by PCR and an automated fluorescence sequencer with specific primers for the *CHOP*5\'UTR-c.279T\>C and +nt30C\>T genotypes.

We calculated via 70% power and type 1 error probability of 0.05, detectable odds ratios for genotype association tests in our two datasets, using the prevalence of 31.3% for overweight condition \[[@B19]\] and the prevalence of 2.7% for tumors/cancer in the Italian population \[[@B20]\].

Via Chi-Square test statistics, we tested the alleles for departure from Hardy-Weinberg equilibrium (HWE) in our two datasets in cases and control subject groups, separately.

Via the Mantel-Haenszel algorithm, we tested the *CHOP*5\'UTR-c.279T\>C and +nt30C\>T genotypes for association with BMI ≥ 25 and with tumors/cancer.

In addition, we performed model free and parametric haplotype associations tests (dominant, recessive and additive models) for BMI ≥ 25 and for tumors/cancer, independently (EHPLUS software) \[[@B21]\].

Results
=======

Risk odds ratios of 0.248/2.943 for genotypes association tests were detectable in the pre-obesity dataset. Risk odds ratios of 8.210 for genotype association tests were detectable in the tumors/cancer dataset.

All alleles tested in each group of the two datasets of BMI ≥ 25 and of tumors/cancer were not in departure from HWE.

We did not identify in our dataset any significant and valid association of the *CHOP*5\'UTR-c.279T\>C and +nt30C\>T genotype variants with BMI ≥ 25 (Table [1](#T1){ref-type="table"}) as well as with tumors/cancer patients (Table [2](#T2){ref-type="table"}).

###### 

*CHOP*5\'UTR-c.279T\>C and +nt30C\>T genotype association with overweight condition (BMI ≥ 25).

  **Genotype**          **45 Cases**   **44 Control Subjects**   **χ^2^**   **2-t P**   **OR**   **95% C.I**.          
  --------------------- -------------- ------------------------- ---------- ----------- -------- -------------- ------ ------------
  **5\'UTRc.279T\>C**   \+             \-                        \+         \-                                         
                                                                                                                       
  TT                    31             14                        26         18          0.92     0.33           1.53   0.59--4.02
                                                                                                                       
  CT                    13             32                        18         26          1.41     0.23           0.59   0.22--1.55
                                                                                                                       
  CC                    1              44                        0          44          0.98     0.32           8      0.06--8
                                                                                                                       
  **+nt30C\>T**                                                                                                        
                                                                                                                       
  TT                    0              45                        0          44                                  NA     
                                                                                                                       
  CT                    13             32                        17         27          0.94     0.33           0.65   0.24--1.71
                                                                                                                       
  CC                    32             13                        27         17          0.94     0.33           1.55   0.58--4.13

X^2^= Chi-Square, 2-t P = 2-tailed p-value, OR = odds ratio,

C.I. = confidence interval

###### 

*CHOP*5\'UTR-c.279T\>C and +nt30C\>T genotype association with tumors/cancer.

  **Genotype**          **54 Cases**   **43 Control Subjects**   **χ^2^**   **2-t P**   **OR**   **95% C.I**.          
  --------------------- -------------- ------------------------- ---------- ----------- -------- -------------- ------ -------------
  **5\'UTRc.279T\>C**   \+             \-                        \+         \-                                         
                                                                                                                       
  TT                    35             19                        27         16          0.04     0.83           1.09   0.44--2.73
                                                                                                                       
  CT                    17             37                        14         29          0.01     0.91           0.95   0.37--2.45
                                                                                                                       
  CC                    2              52                        2          41          0.05     0.81           0.79   0.08--8.28
                                                                                                                       
  **+nt30C\>T**                                                                                                        
                                                                                                                       
  TT                    2              52                        1          42          0.15     0.69           1.62   0.11--46.73
                                                                                                                       
  CT                    17             37                        16         27          0.35     0.55           0.78   0.31--1.96
                                                                                                                       
  CC                    35             19                        26         17          0.19     0.66           1.20   0.48--2.99

X^2^= Chi-Square, 2-t P = 2-tailed p-value, OR = odds ratio,

C.I. = confidence interval

The parametric and non-parametric *CHOP*5\'UTR-c.279T\>C and +nt30C\>T haplotype association tests with BMI ≥ 25 as well as with tumors/cancer were also not significant (data not shown).

Discussion
==========

*CHOP*gene encodes a C/EBP (CCAAT/enhancer binding protein family)-homologous nuclear protein that acts as dominant-negative inhibitor of gene transcription through dimerization with C/EBP \[[@B22]\]. *CHOP*is implicated in programmed cell death \[[@B12]\]. Several studies reported *CHOP*gene rearrangement and/or fusion with other genes (such as *EWS-CHOP*and *TLS/FUS-CHOP*) in tumors/cancer \[[@B13],[@B18]\].

Cellular and endoplasmic reticulum (ER) stress, occurring in response to toxic and metabolic insult, is a powerful inducer of CHOP \[[@B12]\]. ER stress down-regulates insulin receptor signaling and triggers insulin resistance \[[@B9]\]. Furthermore, insulin increases *CHOP*expression in adipocyte cells \[[@B23]\], and CHOP inhibits adipocyte differentiation \[[@B8]\]. Thus, CHOP deficiency may contribute to obesity \[[@B11]\].

Glucotoxicity induces cellular stress \[[@B24]\], which activates CHOP \[[@B12]\]. Thus, hyperglycemia may cause CHOP-mediated beta-cell apoptosis and may contribute to T2D. Interestingly, *CHOP*5\'UTR-c.279T\>C and +nt30C\>T haplotype variants are significantly associated with early-onset T2D under a recessive and additive model \[[@B7]\]. For all the above reasons, *CHOP*is not only a T2D gene, but it is also an obesity candidate gene as well as a gene potentially predisposing to tumors and/or cancer. Other T2D genes, such as *HNF-1 beta*and *JAZF1*, have already been associated with prostate cancer \[[@B4]-[@B6]\]. Of note, while the prostate cancer risk *HNF-1 beta*variant decreases the risk of T2D \[[@B4]\], variants of *JAZF1*gene are associated with both increased risk for T2D and for prostate cancer \[[@B5],[@B6]\].

However, no study has up to date investigated the susceptibility role of *CHOP*common variants in pre-obese and tumor/cancer patients. This is the first association study focusing on *CHOP*gene variants in human genomic DNA samples of overweight subjects and tumor/cancer cases.

In our study, we did not identify any association between *CHOP*5\'UTR-c.279T\>C and +nt30C\>T genotype and haplotype variants with pre-obesity and with tumors/cancer. If the *CHOP*gene variants tested were to contribute to overweight condition and/or tumors/cancer with a modest size effect, our datasets are too small to detect such effects. However, we could at least exclude in the current study a *CHOP*5\'UTR-c.279T\>C and +nt30C\>T variant risk effect of about 3 for pre-obesity and of about 8 for tumors/cancer.

Conclusion
==========

In summary, we conclude that *CHOP*5\'UTR-c.279T\>C and +nt30C\>T variants, both at genotype and at haplotype level, are not contributing to the overweight condition and tumors/cancer in our dataset. However, other studies are warranted to further exclude the role of any other *CHOP*variants in obesity and in tumor/cancer predisposition. Since obesity is a preventable associated factor in several tumors/cancer \[[@B25]\] and in other co-morbidities \[[@B26]\], and, since tumors and cancer may be prevented and/or diagnosed at an earlier stage, genetic studies to identity overweight risk predisposition as well as tumors/cancer risk susceptibility should be further performed to guide disease prediction and prevention.
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